Defence's
AccumTM-HPV
vaccine formulation (AccuVAC-PT009) activates a 36-fold higher
humoral response compared to Gardasil-9
Vancouver, BC,
Canada, January 26th,
2022 - InvestorsHub NewsWire - Defence Therapeutics Inc.
("Defence"
or the "Company"
CSE:DTC,
USOTC:DTCFF), a
pre-clinical biotechnology company developing various
immune-oncology products, is pleased to announce the development of
AccuVAC-PT009, a new protein-based HPV vaccine, leading to a
humoral response bypassing Gardasil-9 (Merck) immunogenicity in
animals.
ACCUMTM
is a platform technology
100% owned by Defence Therapeutics. ACCUMTM
is an enabling technology
as it can be used to enhance the intracellular accumulation of
various proteins of pharmacological interests into any target
cells. As such, it is currently used by Defence for the development
of several anti-cancer and COVID vaccines, as well as for the
improvement of approved or in development antibody-drug
conjugates.
To further demonstrate
the ACCUMTM
versatility, the Defence
research and development team designed and engineered a HPV vaccine
(a mix of the same 9 HPV-derived L1 proteins used in Gardasil-9)
and compared its immunogenicity to a group of Gardasil-9-immunized
animals. Compared to Gardasil-9, AccuVAC-PT009 triggers an
impressive 27- and 36-fold increase in antibody titer at 4- and
6-weeks post-immunization respectively.
"We are extremely proud
to demonstrate again how ACCUMTM
can be exploited and
applied to significantly improve any protein-based vaccine. Not
only can this vaccine have a tremendous impact on improving the
immunogenicity of the commercialized Gardasil-9, but it can in
addition lower the dosing regimen (at least by 10-fold) yet
triggering similar or more potent humoral response", says Mr.
Plouffe, the CEO of Defence.
According to Fortune Business
Insights, the global HPV vaccine market size was valued at $3.80 Bn
in 2019 & is projected to reach $12.69 Bn by 2027, with a CAGR
of 16.3%.
Defence Therapeutics is
currently working on various scenarios. Although its initial intent
is to pursue the development of its AccuVAC-PT009 HPV vaccine
candidate or even adding other subtypes currently not covered by
Gardasil-9, the company is actively looking for to establish
partnerships with major pharmaceuticals players to bring forward
its vaccine portfolio.
About
Defence:
Defence
Therapeutics is a publicly-traded biotechnology company working on
engineering the next generation vaccines and ADC products using its
proprietary platform. The
core of Defence Therapeutics platform is the ACCUMTM
technology,
which enables precision delivery of vaccine antigens or ADCs in
their intact form to target cells. As a result, increased efficacy
and potency can be reached against catastrophic illness such as
cancer and infectious diseases.
For further
information:
Sebastien Plouffe,
President, CEO and Director
P: (514)
947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary
Statement Regarding "Forward-Looking" Information
This release includes
certain statements that may be deemed "forward-looking statements".
All statements in this release, other than statements of historical
facts, that address events or developments that the Company expects
to occur, are forward-looking statements. Forward-looking
statements are statements that are not historical facts and are
generally, but not always, identified by the words "expects",
"plans", "anticipates", "believes", "intends", "estimates",
"projects", "potential" and similar expressions, or that events or
conditions "will", "would", "may", "could" or "should" occur.
Although the Company believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and actual
results may differ materially from those in the forward-looking
statements. Factors that could cause the actual results to differ
materially from those in forward-looking statements include
regulatory actions, market prices, and continued availability of
capital and financing, and general economic, market or business
conditions. Investors are cautioned that any such statements are
not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on
the beliefs, estimates and opinions of the Company's management on
the date the statements are made. Except as required by applicable
securities laws, the Company undertakes no obligation to update
these forward-looking statements in the event that management's
beliefs, estimates or opinions, or other factors, should
change.
Neither the
CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or
accuracy of this release.
